Health
CureVac’s Covid-19 vaccine induces immune response in study – Clinical Trials Arena
CureVac has reported that the ongoing Phase I study of its Covid-19 vaccine candidate CVnCoV showed that it was well-tolerated across all tested doses ranging from…
CureVac has reported that the ongoing Phase I study of its Covid-19 vaccine candidate CVnCoV showed that it was well-tolerated across all tested doses ranging from 2 to 12µg and induced strong binding and neutralising antibody responses.
The Phase I study is evaluating the safety, reactogenicity and immunogenicity of the investigational vaccine CVnCoV, an optimised, non-chemically modified mRNA that encodes the prefusion stabilised full-length spike protein of the SARS-CoV-2 virus.
Its mode of action…
-
Noosa News22 hours agoThe Pedro Pascal-Led Fantastic Four Face Julia Garner’s Silver Surfer in the New Full ‘First Steps’ Trailer
-
General21 hours agoFrom Humpty Doo to the bush, these voters’ views reflect the challenge for federal politicians
-
General22 hours agoPolice say man shot dead in Footscray had charged at officers armed with knife
-
General19 hours agoNew Zealand wants more ‘automated decision-making’ in its welfare system. Could that lead to Robodebt 2.0?